Eli Lilly’s 2Q17 Earnings Rose 8% Year-over-Year

1 2 3 4 5 6 7 8 9 10
Part 9
Eli Lilly’s 2Q17 Earnings Rose 8% Year-over-Year PART 9 OF 10

Eli Lilly’s Major Developments in 2Q17

Recent developments

Eli Lilly and Company’s (LLY) segmental performance in 2Q17 was positive for its Human Pharmaceuticals segment. But it was negative for its Animal Health segment. Let’s look now at Eli Lilly’s major developments in 2Q17.

Eli Lilly’s Major Developments in 2Q17

Interested in LLY? Don't miss the next report.

Receive e-mail alerts for new research on LLY

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

Commercial developments

Recent commercial developments for Eli Lilly include the following:

  • Eli Lilly repurchased shares worth $200.0 million and distributed dividends of more than $500.0 million to its shareholders in 2Q17.
  • Eli Lilly and KeyBioscience AG announced a collaboration for the development of a dual amylin and calcitonin receptor agonist for the treatment of metabolic disorders, including Type 2 diabetes. The collaboration includes KBP-042, which is in Phase II development. Eli Lilly will make a payment of $55.0 million in 3Q17.
  • Eli Lilly and Nektar Therapeutics entered into a co-development agreement for NKTR-358, which is an investigational treatment for autoimmune and chronic inflammatory conditions. Eli Lilly will pay Nektar Therapeutics ~$150.0 million for the drug upon closing the transaction.

Regulatory developments

Below are the recent regulatory developments for Eli Lilly:

  • The FDA (U.S. Food & Drug Administration) granted priority review to abemaciclib for use in the treatment of metastatic breast cancer, based on the results from the Monarch 1 and Monarch 2 studies.
  • The FDA also approved the use of Alimta in combination with Merck & Co.’s (MRK) Keytruda and carboplatin as a first-line treatment for patients with metastatic non-small cell lung cancer.
  • The FDA granted fast track designation for tanezumab. The drug, co-developed with Pfizer (PFE), is indicated for the treatment of patients with osteoarthritis and chronic lower back pain.
  • Japan’s Ministry of Health, Labour, and Welfare granted marketing authorization for the new drug Olumiant (baricitinib) 2 mg (milligram) and 4 mg tablets for the treatment of rheumatoid arthritis.
To divest the company-specific risks, you can consider the Fidelity MSCI Health Care ETF (FHLC), which holds 2.2% of its total assets in Eli Lilly. FHLC also holds 6.7% in Pfizer (PFE), 5.3% in Merck & Co. (MRK), and 3.1% in Bristol-Myers Squibb (BMY).

Please select a profession that best describes you: